ଓସିମେରଟିନିବ

ଓସିମେରଟିନିବ
Clinical data
Trade names	Tagrisso, others
Synonyms	AZD9291, mereletinib, osimertinib mesilate (JAN JP), osimertinib mesylate (USAN US)
AHFS/Drugs.com	monograph
MedlinePlus	a616005
data	EU EMA: yes; US DailyMed: Osimertinib;
Pregnancy; category	AU: D ; ;
Routes of; administration	By mouth tablets
ATC code	L01EB04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Pharmacokinetic data
Protein binding	Probably high
Metabolism	Oxidation (CYP3A)
Elimination half-life	48 hours
Excretion	Feces (68%), urine (14%)
Identifiers
	IUPAC name N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide;
CAS Number	1421373-65-0;
PubChem CID	71496458;
DrugBank	DB09330;
ChemSpider	31042598;
UNII	3C06JJ0Z2O;
KEGG	D10766;
ChEBI	CHEBI:90943 ;
PDB ligand	YY3 (PDBe, RCSB PDB);
Chemical and physical data
Formula	C28H33N7O2
Molar mass	୪୯୯.୬୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1N(C)CCN(C)C;
	InChI InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32); Key:DUYJMQONPNNFPI-UHFFFAOYSA-N;

ଓସିମେରଟିନିବ, ଏକ ବେପାର ନାମ ଟାଗ୍ରିସୋ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଇଜିଏଫଆର (EGFR) ଜିନରେ କିଛି ପରିବର୍ତ୍ତନ ଥିବା ଅଣ-କୋଷିକା ଫୁସଫୁସ କର୍କଟ (NSCLC)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୪] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ତରଳ ଝାଡ଼ା, ରାସ, ପାଟି ଘାଆ, ଥକ୍କାପଣ ଏବଂ ଯକୃତ ପ୍ରଦାହ ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।^[୫] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନିମୋନିଆ, କ୍ୟୁଟି ବିସ୍ତାର, କାର୍ଡିଓମାୟୋପାଥି ଏବଂ ଆଖି ପ୍ରଦାହ ହୋଇପାରେ। ।^[୫] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୫] ଏହା ଏକ ଟାଇରୋସିନ କାଇନେଜ ଇନହିବିଟର ।^[୫]

୨୦୧୫ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏବଂ ୨୦୧୬ ମସିହାରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଓସିମେରଟିନିବ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୫] ^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ପ୍ରତି ମାସରେ ପ୍ରାୟ ୫,୮୦୦ ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୬] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୧୬,୦୦୦ ଡଲାର ଅଟେ ।^[୭]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.
↑ ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Tagrisso EPAR ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।
↑ ^୩.୦ ^୩.୧ "Tagrisso- osimertinib tablet, film coated". DailyMed. 5 June 2020. Retrieved 16 October 2020.
↑ ^୪.୦ ^୪.୧ "Tagrisso EPAR". European Medicines Agency (EMA). Archived from the original on 17 October 2020. Retrieved 16 October 2020.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Osimertinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 9 November 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1038. ISBN 978-0857114105.
↑ "Tagrisso Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 May 2021. Retrieved 9 November 2021.

[1] "Prescription medicines: registration of new chemical entities in Australia, 2016". Therapeutic Goods Administration (TGA). 21 June 2022. Archived from the original on 10 April 2023. Retrieved 10 April 2023.

[Tagrisso_EPAR-2] ଆଧାର ଭୁଲ: ଅଚଳ <ref> ଚିହ୍ନ; Tagrisso EPAR ନାମରେ ଥିବା ଆଧାର ଭିତରେ କିଛି ଲେଖା ନାହିଁ ।

[USlabel-3] ୩.୦ ^୩.୧ "Tagrisso- osimertinib tablet, film coated". DailyMed. 5 June 2020. Retrieved 16 October 2020.

[EPAR2021-4] ୪.୦ ^୪.୧ "Tagrisso EPAR". European Medicines Agency (EMA). Archived from the original on 17 October 2020. Retrieved 16 October 2020.

[AHFS2021-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ "Osimertinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 January 2021. Retrieved 9 November 2021.

[BNF81-6] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1038. ISBN 978-0857114105.

[7] "Tagrisso Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 May 2021. Retrieved 9 November 2021.

[୧]

[୩]

[୨]

[୪]

[୫]

[୬]

[୭]